Study identification

EU PAS number

EUPAS7953

Study ID

16873

Official title and acronym

PGx7607: PGx evaluation of pyrexia by meta-analysis of melanoma subjects from BRF113710, BRF113929, BRF113683, MEK115306 and MEK116513 (202050)

DARWIN EU® study

No

Study countries

United States

Study status

Finalised
Research institutions and networks

Institutions

Contact details

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact
Pharma.CDR@gsk.com

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

GlaxoSmithKline
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only